Introduction
============

Colorectal cancer (CRC) is the third most prominent type of cancer worldwide, which is commonly diagnosed in patients above the age of 50 years ([@b1-ol-0-0-11894]--[@b3-ol-0-0-11894]). The incidence of CRC among adolescents and young adults has exhibited an increase over the past decades ([@b1-ol-0-0-11894]--[@b3-ol-0-0-11894]), particularly in patients aged 20--39 years ([@b4-ol-0-0-11894],[@b5-ol-0-0-11894]). Early-onset CRC usually presents at an advanced stage at the time of diagnosis with a more aggressive biological behavior, which is unique to this subset of CRC ([@b6-ol-0-0-11894]--[@b8-ol-0-0-11894]). A study indicated that the prevalence of hereditary cancer syndromes in CRC patients aged 35 years or younger was \~35% ([@b7-ol-0-0-11894]). This group of patients (aged 35 years or younger) has comparatively more concerns in various aspects that require to be addressed (including the impact on fertility) ([@b9-ol-0-0-11894]), which raises a compelling need for the identification of prognostic markers and optimization of treatment strategies. However, studies focusing on the genetic features of early-onset CRC in patients aged 35 or younger are limited ([@b7-ol-0-0-11894]).

The carcinogenesis of CRC is described by a genetic model of cancer comprising the sequential accumulation of genetic alterations. There are two distinct genetic pathways: The adenomatous polyposis coli (APC)/β-catenin pathway, which exhibits sequential alterations of genes including APC, K-RAS proto-oncogene (KRAS) and tumor protein 53 (TP53), and the microsatellite instability (MSI) pathway, which comprises a deficiency in DNA mismatch repair (MMR) genes ([@b10-ol-0-0-11894],[@b11-ol-0-0-11894]). In addition, the methylation of CpG islands, an epigenetic alteration, has been recognized as an early event involved in the development of CRC ([@b12-ol-0-0-11894]). The genetic alterations of non-polyposis CRC in younger patients manifest as Lynch syndrome (LS), which exhibits germline mutations in MMR genes; and sporadic CRC, which presents as more complex and diverse genetic alterations ([@b13-ol-0-0-11894]).

Certain genetic test panels have been reported to be a useful tool with which to identify multiple genetic mutations ([@b14-ol-0-0-11894]). However, the genetic alterations that were identified from these pathways or panels have limited clinical utility at present. The major molecular alterations validated as significant markers are high levels of MSI/defective MMR (MSI-H/dmmr; good prognosis, insensitive to 5-fluorouracil chemotherapy), mutation in the B-Raf proto-oncogene (BRAF) \[poor prognosis, resistance to anti-epidermal growth factor receptor (EGFR) antibodies\] and mutations in KRAS/N-RAS proto-oncogene (NRAS) genes (resistance to anti-EGFR antibodies) ([@b15-ol-0-0-11894],[@b16-ol-0-0-11894]).

More genes, particularly prognosis- and treatment-associated genes, should be identified in order to enhance the current understanding of early-onset CRC. The identification of these genes may aid in the development of more specific and suitable genetic analyses and may also help to improve management strategies. There are certain therapies that were initially used to target specified molecular alterations in a particular tumor type and have been successfully utilized in other cancer types. A successful example of this is the status regarding anaplastic lymphoma kinase (ALK) gene rearrangement, which was initially identified in anaplastic large-cell lymphomas, and is currently an important indicator for ALK inhibitor treatment in lung cancer ([@b17-ol-0-0-11894]). It would be of interest to determine whether CRC exhibits certain genetic mutations that are already considered as prognostic and/or predictive markers in other cancer types and also to determine what the frequencies of these genetic mutations are. Thus, after reviewing the literature and searching certain databases (COSMIC, <https://cancer.sanger.ac.uk/cosmic> and My Cancer Genome, <http://www.mycancergenome.org>), the present study selected 44 exons of 17 genes, which have been reported to be prognostic and/or predictive markers in CRC and other malignancies ([Table SI](#SD1-ol-0-0-11894){ref-type="supplementary-material"}) for analysis. The aim of the present study was to use next-generation sequencing (NGS) to identify these genetic mutations in a cohort of patients with early-onset non-polyposis CRC. Of note, a set of genetic mutations was identified, which was rarely reported previously, as well as other features, which may indicate that this subset of CRC has unique genetic features.

Materials and methods
=====================

### Patient selection

A total of 40 patients aged 35 years or younger who had undergone surgery for CRC at West China Hospital (Sichuan University, Chengdu, Sichuan, China) between November 2014 and May 2015 were selected for the present study, which was performed according to protocols approved by the West China Hospital Institutional Review Board (Chengdu, China). They primarily presented with solitary tumors without polyposis or any clinical history of inflammatory bowel disease. Information regarding medical history and family history and pathological data were collected.

### Immunohistochemistry (IHC) of MMR protein

Tissue sections (4-µm-thick) were cut from the formalin-fixed, paraffin-embedded (FFPE) tumors. The slides had undergone deparaffinization, rehydration and antigen retrieval, and endogenous peroxidase activity was blocked by incubation with 3% H~2~O~2~ at room temperature for 25 min. The sections were then mounted on a DAKO Autostainer Link 48 and then exposed to the ready-to-use mutL homolog 1 (MLH1; cat. no. IR07961), mutS homolog 2 (MSH2; cat. no. IR08561), mutS homolog 6 (MSH6; cat. no. IR08661), PMS1 homolog 2 (PMS2) (cat. no. IR08761) rabbit and mouse monoclonal antibodies (Dako; Agilent Technologies, Inc.) at 37°C for 1 h. The antigen-antibody reaction was visualized with the Envision kit (Dako; Agilent Technologies, Inc). Finally, the slides were counterstained with hematoxylin.

The tumors were considered to be devoid of MLH1, MSH2, MSH6 and PMS2 expression if no nuclear staining of tumor cells was detected. However, tumor cells that were strongly and weakly stained were considered as positive. The surrounding stromal cells, lymphocytes served as an internal positive control ([@b18-ol-0-0-11894]).

### Genomic DNA extraction

The FFPE colorectal tumors obtained during surgery were analyzed and for this, biopsy samples were extracted from them. The sample blocks which harbored tumors that covered \>50% of the area were selected by a pathologist (DJ). The genomic DNA was extracted from the FFPE samples using the QIAamp DNA FFPE Tissue kit (Qiagen GmbH) as per the manufacturer\'s protocol. The DNA concentration was measured using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.) and normalized to 20--50 ng/µl. The DNA samples were then stored at −20°C until use.

### Ion Torrent Personal Genome Machine (PGM) library preparation and sequencing

Libraries were prepared using the CureSeq PAN-Cancer Panel (ACCB Biotech Ltd.) on the Ion Torrent™ System according to the manufacturer\'s protocol. The genomic regions of selected genes ([Table I](#tI-ol-0-0-11894){ref-type="table"}) were amplified using pooled primer pairs, followed by ligation with adaptors and barcodes. The hot points and exons that were tested in the 17 genes are listed in [Table I](#tI-ol-0-0-11894){ref-type="table"}. Following purification, the libraries were quantified using a Qubit dsDNA HS Assay kit on a Qubit 2.0 fluorimeter (Life Technologies; Thermo Fisher Scientific, Inc.) diluted to a concentration of 3 ng/ml and pooled in equal volumes. The library pool was clonally amplified in an emulsion PCR reaction using Ion Sphere Particles on the OneTouch 2 instrument (Life Technologies; Thermo Fisher Scientific, Inc.). Subsequently, template-positive ion sphere particles were enriched on the Ion OneTouch ES (Life Technologies; Thermo Fisher Scientific, Inc.). Following enrichment, sequencing primers and polymerase were added from the Ion PGM™ Sequencing Supplies 200 v2 kit (Life Technologies; Thermo Fisher Scientific, Inc.). The mentioned procedures were performed according to the manufacturer\'s protocol. The libraries were loaded onto an Ion 318 chip (Life Technologies; Thermo Fisher Scientific, Inc.) and sequenced on an Ion Torrent PGM (Life Technologies; Thermo Fisher Scientific, Inc.) instrument to generate the sequencing data.

### Variant calling

The generated data were initially processed using the Ion Torrent pipeline software Torrent Suite (Life Technologies; Thermo Fisher Scientific, Inc.) to generate sequence reads, trim adapter sequences and filter and remove poor signal-profile reads. Initial variant calling from the sequencing data was generated using Torrent Suite Software v3.4 with the plug-in 'variant caller'. In order to eliminate erroneous base calling and generate the final variant calling, the variants in amplicon AMPL339432 (PIK3CA, exon13, ch3: 178938822-178938906) were eliminated as previously described ([@b19-ol-0-0-11894]). The sequence read distribution across the 67 amplicons generated from the 40 FFPE specimens was normalized to 300,000 reads per sample ([Fig. S1](#SD1-ol-0-0-11894){ref-type="supplementary-material"}).

### Somatic mutations and bioinformatic validation

The detected mutations were compared with variants in the 1000 Genomes Project (<https://www.internationalgenome.org>) and 6500 exomes of National Heart, Lung, and Blood Institute Exome Sequencing Project (<https://www.nhlbi.nih.gov>), COSMIC database (<http://cancer.sanger.ac.uk/cosmic>), MyCancerGenome database (<https://www.mycancergenome.org>) and certain pieces of published literature to assess the mutations in CRC in PubMed database using the gene names as keywords.

### Statistical analysis

Categorical variables were examined using the Chi-squared or Fisher\'s exact test. A two-sided P\<0.05 was considered to indicate a statistically significant difference. All the statistical analyses were performed using SPSS software (version 24.0 for Windows; IBM Corp.).

Results
=======

### Clinicopathological characteristics

The clinicopathological features of the patients of the present study are summarized in [Table II](#tII-ol-0-0-11894){ref-type="table"}. The cohort consisted of 22 males and 18 females with a mean age of 30 years (range, 18--35 years). The rectum was the most common tumor site, followed by the right colon and the left colon. Half of the patients presented with stage III carcinoma at the time of diagnosis, followed by stage II, stage I and stage IV. In total, 6 patients had poorly differentiated tumors, including 4 cases of signet ring cell carcinoma. In addition, 15 of the patients had relatives within three generations who had been diagnosed with carcinoma and 9 patients had relatives who were diagnosed with CRC.

### MMR protein expression

Representative IHC images for MMR are presented in [Fig. 1](#f1-ol-0-0-11894){ref-type="fig"}. The results regarding MMR are summarized in [Table III](#tIII-ol-0-0-11894){ref-type="table"}. The absence of at least one MMR protein was observed in 11 tumors. No solitary MLH1 absence was observed. Solitary MSH2 or PMS2 absence was observed in three and one of the cases, respectively. Furthermore, five of the tumors presented with both MSH2 and MSH6 absence and two of the tumors exhibited both MLH1 and PMS2 protein absence. In total, 7 out of the 17 cancers that were located in the right colon presented with MMR protein absence and among the 18 rectal cancers, only 4 samples exhibited MMR protein absence. MMR proteins were observed in all of the 5 cases of cancer of the left colon.

### Genetic mutations detected by NGS

The results regarding genetic mutation are summarized in [Table III](#tIII-ol-0-0-11894){ref-type="table"} and [Fig. 2](#f2-ol-0-0-11894){ref-type="fig"}. In total, 26 of the tumors (26/40, 65%) carried one or more of the tested genetic mutations. Single mutations were observed in 21 of the tumors, double mutations in 3 tumors and three or more gene mutations in 2 tumors. The most common mutated gene was KRAS, followed by phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), BRAF, erb-b2 receptor tyrosine kinase 2 (ERBB2), discoidin domain receptor tyrosine kinase 2 (DDR2), NRAS, KIT proto-oncogene (KIT), TSC complex subunit 1 (TSC1), DNA methyltransferase 3 alpha (DNMT3A) and ABL proto-oncogene 1 (ABL1). The specific codon data are presented in [Table III](#tIII-ol-0-0-11894){ref-type="table"}.

### Correlation between MMR status and genetic mutations

Out of the 11 dMMR tumors, 9 samples (9/11, 81.8%) exhibited genetic mutations in the genes tested in the present study, while only 17 samples of the 29 MMR-proficient (pMMR) tumors exhibited genetic mutations (P=0.158). KRAS/NRAS was mutated in 5 dMMR tumors and in 10 pMMR tumors (P=0.469). PI3KCA was mutated in 5 dMMR tumors and 3 pMMR tumors (P=0.025). KIT and DNMT3A mutations were only detected in dMMR right colon cancers (but not in all dMMR right colon cancers). TSC1 and ABL1 mutations were only observed in pMMR rectal cancers (but not in all pMMR rectal cancers). BRAF, ERBB2 and DDR2 mutations were identified both in dMMR and pMMR cancers (not all cancers). The results are presented in [Fig. 2](#f2-ol-0-0-11894){ref-type="fig"}.

### MMR status and genetic mutations classified by family history

The results regarding MMR status and genetic mutations classified by family history are illustrated in [Fig. 2](#f2-ol-0-0-11894){ref-type="fig"}. All of the 9 patients who had relatives with CRC presented with tumors with dMMR, the prevalence of which differed significantly from the other groups (100 vs. 16.7% of patients with a family history of other cancer types vs. 4% of patients without a family history of cancer; P\<0.001). In total, 8 out of the 9 patients with a family history of CRC presented with mutations in genes that were assessed in the present study. The mutation of PIK3CA was more frequently detected in the group with a family history of CRC compared to that in the other two groups (P=0.01), while the other genetic features exhibited no statistically significant differences ([Fig. 2](#f2-ol-0-0-11894){ref-type="fig"}).

The coincidence of dMMR and genetic mutations occurring simultaneously was not observed in the 6 patients who had relatives with other types of carcinoma. There were genetic mutations in only 3 samples, while dMMR was observed in another single case separately. ERBB2, DDR2, KIT and DNMT3A mutations were only detected in patients who presented with a family history of carcinoma. For the other 25 patients who did not have any family history of cancer, 15 cases exhibited genetic mutations together with pMMR.

Discussion
==========

CRC is recognized as a highly heterogeneous type of tumor at the molecular level ([@b20-ol-0-0-11894]). The most important characteristic of young patients with CRC is considered to be the high prevalence of hereditary cancer syndromes ([@b7-ol-0-0-11894]). However, the results of the present study revealed the genetic features of this subgroup of CRC from a different perspective. The present study focused on the genetic mutations, which are already recognized as prognostic and/or predictive markers in multiple malignancies and various noteworthy results were obtained. These results may aid in the understanding of the genetic features associated with this subset of patients with CRC. Most importantly, these results may serve as a basis to investigate these newly identified mutations in future research.

Early-onset non-polyposis CRC is a distinct entity with unique genetic features. Accumulating data suggest that early-onset CRC may have distinct clinicopathological features, including a more frequent occurrence in the rectum (32-57.7%), manifesting as mucinous (12.6%) or signet ring (10.8%) carcinoma and exhibiting poor differentiation features (20.4%) on histological analysis, and that diagnosis is mostly made at stages III and IV ([@b8-ol-0-0-11894],[@b21-ol-0-0-11894]--[@b23-ol-0-0-11894]). All of these features were also determined in the present study.

In the cohort of the present study, the frequency of loss of MMR function was 27.5%, which may be close to that of CRC in general (15-20%) ([@b24-ol-0-0-11894]). The mutation frequencies in the RAS signaling pathway (KRAS, 35%; NRAS, 2.5%; and BRAF, 5%) and the PI3K/AKT pathway (PIK3CA, 20%) were similar to the general CRC series (KRAS, 35%; NRAS, 1--6%; BRAF, 5--15%; and PIK3CA, 10--30%) ([@b25-ol-0-0-11894]--[@b27-ol-0-0-11894]). However, certain distinct molecular features were still recognized. First, mutations were identified in certain receptor tyrosine kinases (ERBB, 2.5%; DDR, 2.5%; KIT, 2.5%; and ABL1, 2.5%) which have been rarely studied in CRC. This result indicates that these receptor tyrosine kinases, which participate in several signaling pathways, may be involved in the development of CRC. Furthermore, these tested genes are mutated more frequently in dMMR (81.8%) tumors than in pMMR (58.6%) tumors. This result is in accordance with the observations of a previous study, which suggests that multiple genes, including transforming growth factor beta receptor 2 (TGFBR2; \~90%, TGFB signaling), activin A receptor type 2A (\~86%, activin signaling), BAX (\~50%, apoptosis) and phosphatase and tensin homolog (\~30%, growth regulation) are frequently mutated in MSI-H/dmmr CRC ([@b28-ol-0-0-11894]). Finally, the association of the MMR status with genetic mutations may be classified based on family history. Patients with a family history of CRC exhibited a higher mutational load in the present study.

Another gene that should be mentioned is DNMT3A, a DNA methyltransferase and an epigenetic modifier. This gene has mutations that may be detected in \~20% of acute myeloid leukemia and is considered to be a marker of poor prognosis ([@b29-ol-0-0-11894],[@b30-ol-0-0-11894]). However, DNMT3A has not been identified in CRC ([@b31-ol-0-0-11894],[@b32-ol-0-0-11894]). In the present study, a tumor sample from a 33-year-old patient exhibited a DNMT3A mutation and the absence of MSH2 protein expression. Of note, both parents of this patient had CRC at the age of 45 and 56 years, respectively. Further research is required on this particular gene, since there may be a noteworthy biological association.

Certain recommendations may be made regarding stratified genetic analysis for early-onset non-polyposis CRC. The genetic features discovered in the present study may aid clinicians in the development of more effective strategies with which to analyse genetic mutations in early-onset CRC. First, this involves testing for more RAS gene mutations. The RAS gene status is crucial for patients who are being considered for anti-EGFR antibody therapy ([@b33-ol-0-0-11894]). For early-onset CRC, it may be necessary to test for multiple RAS gene mutations, as the mutation may occur at rare locations that render treatment ineffective. This result is consistent with the findings of a previous study, which suggested testing for broad RAS genes ([@b34-ol-0-0-11894]). Furthermore, it is advisable to provide a more extensive genetic analysis for patients with early-onset CRC with dMMR. It has been observed that dMMR tumors presented with more genetic mutations in comparison to pMMR cancers. In addition, it is advised that more extensive gene testing is considered for patients with a family history of CRC, even in cases in which the MSI-H/dMMR status is fully known. In the present study, almost all patients who were related to individuals with CRC had both dMMR status and genetic mutations. Finally, for patients with no family history of cancer, or those with a family history of other cancer types, it is important to further understand the status of other genes, even though the tumors do not have dMMR status or may not be LS, since 50--60% of the patients presented with other genetic mutations in the present study. On the other hand, this suggests that 40--50% of tumors from these two groups exhibited genetic wild-type mutations based on the testing results from the current 17-gene panel. Thus, a larger number of such cases require to be investigated and other types of genetic alterations, other genes or even epigenetic modifications require to be explored in future research.

There are various challenges and opportunities in treating non-polyposis early-onset CRC. Emerging evidence suggests that early-onset CRC has a more progressive biological behavior and a worse prognosis ([@b6-ol-0-0-11894],[@b35-ol-0-0-11894]). This subset of patients has comparatively more concerns in a number of aspects, including the effects of treatment on fertility ([@b8-ol-0-0-11894]). These features raise a compelling concern as to the identification of prognostic markers and optimal treatment strategies, which may differ from the older-aged subset of patients.

The present study not only identified certain mutations in various pathways that may be considered as prognostic and predictive markers, but also provided insight into therapy to be identified and developed in future research. Due to the mutations detected in the present study, it is suggested that these receptor tyrosine kinases and certain rarely reported genes should be investigated for non-polyposis early-onset CRC. Furthermore, it is crucial that further research determines whether these targeted agents may also be efficient in early-onset CRC due to the fact that there are established treatment strategies available for these kinases that are normally utilized in other cancer types ([@b36-ol-0-0-11894]--[@b38-ol-0-0-11894]). Continued focus on this tumor entity may provide an opportunity to identify more targetable genetic changes that may improve the current understanding and treatment of this disease.

It should be noted that the present study still has certain limitations. One limitation is the relatively small sample size in the present study. Although unique genetic features of patients with CRC aged ≤35 years were identified, only 40 patients were included. However, the incidence of early-onset CRC is relatively low, particularly in patients aged ≤35 years (\~1.5% in all CRC patients) ([@b5-ol-0-0-11894]). Furthermore, only the MMR IHC analysis rather than both MMR and MSI analysis was performed in the present study. However, according to the high consistency (\>95%) between MMR IHC and MSI PCR results reported ([@b39-ol-0-0-11894]), the MMR status may precisely represent the MSI status and vice versa. Another limitation is that a 17-gene panel with testing in hot mutational spots on 44 exons was applied, which do not include intron mutations. Finally, the number of selected genes was limited, while the major goal of the present study was to reveal the genetic mutations that are relevant to treatment and prognosis. The panel used in the present study included genes that are biomarkers for the treatment and prognosis in multiple cancer types and certain genes which have targeted therapeutic agents in clinical practice or other studies. Therefore, further studies using larger sample sizes and investigating more genetic alterations are required in order to clarify the genetic alterations occurring in young patients with CRC.

In conclusion, the present pilot study tested genetic mutations in 40 patients with early-onset non-polyposis CRC using the NGS technique. The results reveal genetic mutations at different frequencies and a possible association between the tested genes with the MMR status or with family history. The present study provides evidence that may aid in the understanding of the genetic features of patients with early-onset CRC and provides insight into potential gene-targeted therapeutic agents for early-onset non-polyposis CRC. However, investigation of a greater number of such cases is required in order to obtain further information and to confirm the present findings.
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![Images of MMR proteins assessed by immunohistochemistry on paraffin-embedded colorectal cancer specimens. (A) Positive expression of MLH1 protein (magnification, ×200). (B, C and D) Lack of expression of (B) MSH2, (C) MSH6 and (D) PMS2 protein (magnification, ×200). Positive expression is defined as the MMR protein being expressed in the tumor cell nucleus. A negative result is defined as the absence of nuclear staining detected in tumor cells, while the surrounding stromal cells and lymphocytes present with staining and serve as an internal positive control. MMR, mismatch repair; MLH1 mutL homolog 1, DNA mismatch repair protein MLH, putative; MSH2, mutS homolog 2; MSH6, mutS homolog 6; PMS2, PMS1 homolog 2, mismatch repair system component.](ol-20-04-11894-g00){#f1-ol-0-0-11894}

![Family history, MMR status and genetic mutations for each sample. The association between genetic mutation and family history or the MMR status is provided. Family history and MMR status are represented by differently colored bars or circles. For family history (first row in the figure), red represents the cases (cases from 1 to 9) with a family history of CRC, yellow represents the cases (cases from 10 to 15) with a family history of other types of cancer and blue represents the cases (cases from 16 to 40) without any family history of cancer. For the MMR status (third row in the figure), the solid black circle represents the dMMR status (loss of expression of at least one MMR protein), the hollow black circles represent the pMMR status (case exhibits positivity for MLH, MSH2, MSH6 and PMS2 proteins). The grid figure shows the genetic mutations of each sample (grey grids represent the cases without genetic mutations tested in the experiment, while the genetic mutational cases are colored differently according to their family history status) and all the tested genes in the study are listed on the left. The bar chart on the right illustrates the percentages of mutational cases with a different family history (differently colored bars indicate a different family history status) for each gene. For instance, the top bar indicates that 35% of the cases in this group of patients had a KRAS gene mutation, of which 10% of total cases had a family history of CRC (red bar), while the other 25% of total cases had no family history of cancer (blue bar). The lower bar chart illustrates the percentages of dMMR cases (black bars) and the percentages of genetic mutational cases (differently colored bars based on different family history) classified by three different family history statuses (colored differently on the horizontal axis). For instance, for the cases with a family history of CRC (red horizontal axis), 100% showed dMMR (black bar on the left) and 88.9% of these cases (patients with CRC family history) had genetic mutations (red bar). \*P\<0.05 (patients with CRC family history vs. patients with other cancer history and vs. patients with no family history). CRC, colorectal cancer; MMR, mismatch repair; d/pMMR, MMR deficient/proficient; KRAS, KRAS proto-oncogene, GTPase; NRAS, NRAS proto-oncogene; BRAF, B-Raf proto-oncogene, serine/threonine kinase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; KIT, KIT proto-oncogene, receptor tyrosine kinase; PDGFRA, platelet derived growth factor receptor alpha; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; DDR2, discoidin domain receptor tyrosine kinase 2; GTPase; ALK, ALK receptor tyrosine kinase; RET, ret proto-oncogene; SMO, smoothened, frizzled class receptor; TSC1, TSC complex subunit 1; FLT3, fms related receptor tyrosine kinase 3; NPM1, nucleophosmin 1; DNMT3A, DNA methyltransferase 3 alpha; ABL1, ABL proto-oncogene 1.](ol-20-04-11894-g01){#f2-ol-0-0-11894}

###### 

Detected gene panel and mutation sites used in the present study.

  Gene name   Detected mutation sites
  ----------- ----------------------------------------------------------------------------------------
  KRAS        Exons 2 and 3
  NRAS        Exons 2 and 3
  BRAF        Exons 11 and 15
  PIK3CA      Exons 9 and 20
  KIT         Exons 9, 11, 13, 14 and 17
  PDGFRA      Exons 12, 14 and 18
  EGFR        Exons 18, 19, 20 and 21
  ERBB2       Exon 20
  DDR2        Exon 18
  ALK         Codon 1196, 1202 and 1206 at exon 23, and codon 1269 at exon 25
  RET         Codon 634 at exon 11, codon 918 at exon 16
  SMO         Codon 473 at exon 8
  TSC1        Exon 15
  FLT3        Codon 835 at exon 20, exon 14 and 15
  NPM1        Exon 11
  DNMT3A      Codon 882 at exon 23, exons 15--22
  ABL1        Codons 253--255 at exon 4, codons 299 and 317 at exon 5, and codons 351--359 at exon 6

KRAS, KRAS proto-oncogene, GTPase; NRAS, NRAS proto-oncogene; BRAF, B-Raf proto-oncogene, serine/threonine kinase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; KIT, KIT proto-oncogene, receptor tyrosine kinase; PDGFRA, platelet derived growth factor receptor alpha; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; DDR2, discoidin domain receptor tyrosine kinase 2; GTPase; ALK, ALK receptor tyrosine kinase; RET, ret proto-oncogene; SMO, smoothened, frizzled class receptor; TSC1, TSC complex subunit 1; FLT3, fms related receptor tyrosine kinase 3; NPM1, nucleophosmin 1; DNMT3A, DNA methyltransferase 3 alpha; ABL1, ABL proto-oncogene 1.

###### 

Patient demographics and clinicopathological characteristics.

  Case no.   Age (years)   Gender   Family history (number of relatives with cancer)     Tumor site    Differentiation^[a](#tfn2-ol-0-0-11894){ref-type="table-fn"}^   Perineural invasion   AJCC stage
  ---------- ------------- -------- ---------------------------------------------------- ------------- --------------------------------------------------------------- --------------------- ------------
  C1         28            F        1, FDR with CRC                                      Right colon   2                                                               No                    IIIb
  C2         34            M        1, FDR with CRC                                      Right colon   2                                                               No                    IIa
  C3         31            F        1, FDR with CRC                                      Right colon   1                                                               No                    IIa
  C4         26            F        1, FDR with CRC                                      Right colon   3                                                               No                    IIIb
  C5         31            F        1, FDR with CRC                                      Rectum        2                                                               No                    IIb
  C6         33            M        2, FDR with CRC                                      Right colon   1                                                               No                    IIa
  C7         33            M        1, SDR with CRC                                      Rectum        3                                                               No                    IIIc
  C8         34            F        1, SDR with CRC                                      Rectum        1                                                               No                    I
  C9         34            M        2, SDR with CRC; 1, TDR with CRC                     Rectum        2                                                               No                    IIIc
  C10        34            M        1, FDR with other cancer                             Right colon   2                                                               Yes                   IIIb
  C11        33            F        1, FDR with other cancer                             Right colon   2                                                               No                    IIIb
  C12        33            M        1, FDR with other cancer                             Right colon   2                                                               No                    IIa
  C13        31            M        1, FDR with other cancer; 1, SDR with other cancer   Rectum        2                                                               No                    IVa
  C14        31            M        1, SDR with other cancer                             Right colon   2                                                               No                    IIIb
  C15        25            M        1, SDR with other cancer                             Rectum        2                                                               No                    I
  C16        27            M        None                                                 Right colon   1                                                               No                    IIc
  C17        26            M        None                                                 Left colon    2                                                               No                    IIb
  C18        27            F        None                                                 Rectum        2                                                               No                    IIIb
  C19        31            M        None                                                 Rectum        3                                                               No                    IIIb
  C20        31            M        None                                                 Rectum        2                                                               No                    IIIa
  C21        27            M        None                                                 Rectum        1                                                               No                    I
  C22        18            M        None                                                 Right colon   3                                                               No                    IIIc
  C23        23            M        None                                                 Right colon   3                                                               No                    IIIb
  C24        30            F        None                                                 Left colon    2                                                               No                    IIIb
  C25        27            F        None                                                 Rectum        3                                                               No                    IIa
  C26        33            F        None                                                 Rectum        2                                                               No                    IIIb
  C27        29            M        None                                                 Left colon    2                                                               No                    IIIc
  C28        28            M        None                                                 Left colon    1                                                               No                    IIb
  C29        34            F        None                                                 Right colon   2                                                               No                    IIIa
  C30        28            F        None                                                 Right colon   2                                                               No                    IIIa
  C31        35            F        None                                                 Right colon   2                                                               No                    IIIb
  C32        35            F        None                                                 Right colon   2                                                               No                    IIb
  C33        30            F        None                                                 Rectum        2                                                               No                    IV
  C34        26            F        None                                                 Rectum        2                                                               Yes                   IV
  C35        34            M        None                                                 Rectum        1                                                               No                    Ib
  C36        33            M        None                                                 Left colon    2                                                               No                    IIIb
  C37        35            F        None                                                 Right colon   2                                                               No                    IIIc
  C38        27            F        None                                                 Rectum        2                                                               No                    IIb
  C39        32            M        None                                                 Rectum        2                                                               No                    IIb
  C40        35            M        None                                                 Rectum        2                                                               No                    IIa

Degree of differentiation: 1, well; 2, intermediate; 3, poor. F, female; M, male; CRC, colorectal cancer; FDR, first-degree relative; SDR, second-degree relative; TDR, third-degree relative; AJCC, American Joint Committee on Cancer.

###### 

Mismatch repair status and genetic mutations present in this group of early-onset nonpolyposis colorectal cancers.

  A, Family history of CRC                                                                                                                                                                                  
  --------------------------------------------- ------------------------------------------------------------------ ------------ ---------------- ------------ ---------------- -------- ---------- -------- ---------
  C1                                            MSH2(−)                                                            PIK3CA       p.E545G                                                                     
  C2                                            MLH1(−), PMS2(−)                                                   KRAS         p.G12D           PIK3CA       p.H1047R         KIT      p.L682fs   DDR2     p.V797F
  C3                                            MSH2(−), MSH6(−)                                                   KRAS         p.G13D                                                                      
  C4                                            MSH2(−), MSH6(−)                                                   ERBB2        p.V777M          KRAS         p.G12D                                        
  C5                                            MSH2(−), MSH6(−)                                                   PIK3CA       p.H1047R                                                                    
  C6                                            MSH2(−)                                                            PIK3CA       p.H1047Y         DNMT3A       p.R882H          DNMT3A   p.A741V    DNMT3A   p.A572G
  C7                                            PMS2(−)                                                            KRAS         p.G13D           BRAF         p.V600E                                       
  C8                                            MSH2(−), MSH6(−)                                                   PIK3CA       p.E545K                                                                     
  C9                                            MSH2(−), MSH6(−)                                                   WT                                                                                       
                                                                                                                                                                                                            
  **B, Family history of other cancer types**                                                                                                                                                               
                                                                                                                                                                                                            
  **Case no.**                                  **MMR expression^[a](#tfn3-ol-0-0-11894){ref-type="table-fn"}^**   **Gene 1**   **Mutation 1**                                                              
                                                                                                                                                                                                            
  C10                                           MLH1(−), PMS2(−)                                                   WT                                                                                       
  C11                                           (+)                                                                WT                                                                                       
  C12                                           (+)                                                                ERBB2        p.C805S                                                                     
  C13                                           (+)                                                                PIK3CA       p.E545K                                                                     
  C14                                           (+)                                                                WT                                                                                       
  C15                                           (+)                                                                DDR2         p.V797L                                                                     
                                                                                                                                                                                                            
  **C, No family history of cancer**                                                                                                                                                                        
                                                                                                                                                                                                            
  **Case no.**                                  **MMR expression^[a](#tfn3-ol-0-0-11894){ref-type="table-fn"}^**   **Gene 1**   **Mutation 1**   **Gene 2**   **Mutation 2**                                
                                                                                                                                                                                                            
  C16                                           MSH2(−)                                                            KRAS         p.G12D                                                                      
  C17                                           (+)                                                                WT                                                                                       
  C18                                           (+)                                                                WT                                                                                       
  C19                                           (+)                                                                WT                                                                                       
  C20                                           (+)                                                                NRAS         p.G12D                                                                      
  C21                                           (+)                                                                ABL1         p.V323F                                                                     
  C22                                           (+)                                                                WT                                                                                       
  C23                                           (+)                                                                WT                                                                                       
  C24                                           (+)                                                                KRAS         p.G12D                                                                      
  C25                                           (+)                                                                KRAS         p.G13D           PIK3CA       p.E545K                                       
  C26                                           (+)                                                                WT                                                                                       
  C27                                           (+)                                                                BRAF         p.V600E                                                                     
  C28                                           (+)                                                                KRAS         p.Q61L                                                                      
  C29                                           (+)                                                                KRAS         p.G12V                                                                      
  C30                                           (+)                                                                KRAS         p.G12D                                                                      
  C31                                           (+)                                                                PIK3CA       p.T1025S                                                                    
  C32                                           (+)                                                                WT                                                                                       
  C33                                           (+)                                                                KRAS         p.G12D                                                                      
  C34                                           (+)                                                                WT                                                                                       
  C35                                           (+)                                                                WT                                                                                       
  C36                                           (+)                                                                WT                                                                                       
  C37                                           (+)                                                                KRAS         p.G12V                                                                      
  C38                                           (+)                                                                KRAS         p.G12V                                                                      
  C39                                           (+)                                                                TSC1         p.Q654E                                                                     
  C40                                           (+)                                                                KRAS         p.G12V                                                                      

(+) indicates that the four tested MMR proteins (MLH1, MSH2, MSH6, PMS2) are positive; protein of negative expression are listed. The order of gene mutation is listed by the read number of each mutation. MMR, mismatch repair; CRC, colorectal cancer; WT, wild-type; KRAS, KRAS proto-oncogene, GTPase; NRAS, NRAS proto-oncogene; BRAF, B-Raf proto-oncogene, serine/threonine kinase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; KIT, KIT proto-oncogene, receptor tyrosine kinase; ERBB2, erb-b2 receptor tyrosine kinase 2; DDR2, discoidin domain receptor tyrosine kinase 2; GTPase; TSC1, TSC complex subunit 1; DNMT3A, DNA methyltransferase 3 alpha; ABL1, ABL proto-oncogene 1.

[^1]: Contributed equally
